From "not done" to "not done", the company refines the management of technological transformation projects.
Release time:
2021-06-01
News from our newspaper In order to further strengthen the management of technological transformation projects, improve the success rate and return on investment of technological transformation projects, and better and faster improve the competitiveness of enterprises, the company has formulated and issued the "Supplementary Regulations on the Management of Technological Transformation Projects" according to the requirements of the "Engineering Project Management System". In addition to stipulating the procedures for the approval and implementation of technological transformation projects, in particular, the scientific nature of the project, effectiveness, success rate, rate of return and other requirements.
"Supplementary Provisions on the Management of Technological Transformation Projects" is based on the original "Engineering Project Management System", in order to improve the success rate and return on investment of technological transformation projects, and to improve the competitiveness of various enterprises better and faster. For the purpose of power, it is formulated in detail for the management of technological transformation projects, and is applicable to group companies and their wholly-owned and holding subsidiaries. The supplementary provisions put forward specific requirements for the establishment of technical transformation projects, the preparation of transformation plans, project declaration and approval, implementation and acceptance evaluation. For example, the project initiation content requires "including the project name, implementation location, preliminary renovation plan, expected renovation effect, approximate renovation cost, project leader, completion time, etc." and "multi-point renovation of the same renovation content (batch upgrading of similar equipment) shall not be initiated separately"; The preparation of the renovation plan requires "scientific and detailed investigation, analysis and demonstration, which must be forward-looking and advanced, it is also necessary to match and be compatible with the upper and lower technologies and production links to ensure that the corresponding control indicators reach the leading position in the industry after the transformation. The application of new technologies" requires investigation and study in the applied units, understanding and mastering the technical principles, and ensuring the one-time success of the transformation. "The transformation plan" requires scientific and reasonable investment budget and rate of return calculation, except for the projects of technological transformation required by policies, in principle, the rate of return on investment for technological transformation projects shall not be less than 20% ". The acceptance evaluation after the implementation of the technical transformation project has also changed from the common "not done" to the emphasis on "not done", that is, from the actual effect after the technical transformation project is put into operation (use), it is divided into four grades: "excellent", "up to standard", "not up to standard" and "poor; the acceptance evaluation results of the project implementation process management are divided into three levels:" standard "," basic standard "and" non-standard ", and the project leader or enterprise management team will be given corresponding rewards and punishments according to the different levels.
(Reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page